抑制UCP2增强视网膜内皮糖酵解促进早产儿视网膜病变模型中的生理性视网膜血管发育
研究在大鼠50/10氧诱导视网膜病变(OIR)模型中检验解偶联蛋白2(UCP2)通过干扰葡萄糖转运蛋白1(Glut1)的葡萄糖摄取而延迟生理性视网膜血管发育(PRVD)的假说。结果显示OIR幼鼠视网膜Glut1降低、UCP2升高且无血管区增加,腹腔注射UCP2抑制剂京尼平可增加Glut1并减少无血管区,同时减少病理性新生血管并改善视网膜电图振幅。作者认为增加视网膜内皮葡萄糖摄取以延长PRVD可能成为预防严重早产儿视网膜病变和视力丧失的策略。
要点
- OIR幼鼠p14时视网膜Glut1降低、UCP2升高,无血管区较房间空气组增加。
- 腹腔注射京尼平增加视网膜Glut1并减少无血管区,p18病理性新生血管减少。
- 京尼平或敲低UCP2增加hRMVECs的Glut1、葡萄糖摄取、ATP生成和VEGF诱导的p-VEGFR2及细胞增殖。
核心结论
- 通过增加视网膜内皮葡萄糖摄取来延长生理性视网膜血管发育,可能成为预防严重早产儿视网膜病变和视力丧失的策略。
研究设计与样本
- 研究采用大鼠50/10氧诱导视网膜病变(OIR)模型,将OIR与房间空气(RA)幼鼠在出生后第14天(p14)比较视网膜Glut1和UCP2。
- OIR和RA幼鼠从p3至p13每隔一天腹腔注射UCP2抑制剂京尼平或对照,p14分析无血管/总视网膜面积(AVA)、视网膜UCP2和Glut1蛋白印迹及Glut1免疫染色。
- p18分析玻璃体内新生血管/总视网膜面积(IVNV),p26进行视网膜电图检查。
- 在人视网膜微血管内皮细胞(hRMVECs)中,用京尼平预处理或转染UCP2siRNA、Glut1siRNA或对照siRNA,与VEGF或PBS孵育后检测Glut1、磷酸化VEGFR2(p-VEGFR2)、葡萄糖摄取、三磷酸腺苷(ATP)生成和细胞增殖。
主要发现
- p14时OIR幼鼠较RA视网膜无血管/总视网膜面积增加,视网膜Glut1降低、UCP2升高。
- 腹腔注射京尼平增加视网膜Glut1并减少无血管/总视网膜面积。
- 与对照相比,京尼平处理或敲低UCP2显著增加hRMVECs的Glut1、葡萄糖摄取、ATP生成、VEGF诱导的p-VEGFR2和细胞增殖。
- 敲低Glut1抑制VEGF诱导的p-VEGFR2。
- 京尼平处理的OIR幼鼠p14无血管/总视网膜面积减少,p18玻璃体内新生血管/总视网膜面积减少,p26视网膜电图a波和b波振幅增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We address the hypothesis that uncoupling protein 2 (UCP2), a cellular glucose regulator, delays physiologic retinal vascular development (PRVD) by interfering with glucose uptake through glucose transporter 1 (Glut1). METHODS: In the rat 50/10 oxygen-induced retinopathy (OIR) model, retinal Glut1 and UCP2 were measured and compared to room air (RA)-raised pups at postnatal day 14 (p14). Pups in OIR and RA received intraperitoneal genipin, an UCP2 inhibitor, or control every other day from p3 until p13. Analyses at p14 included avascular/total retinal area (AVA), Western blots of retinal UCP2 and Glut1, and immunostaining of Glut1 in retinal cryosections. Intravitreal neovascular/total retinal area (IVNV) was analyzed at p18, and electroretinograms were performed at p26. Glut1 and phosphorylated VEGFR2 (p-VEGFR2), glucose uptake, adenosine triphosphate (ATP) production, and cell proliferation were measured in human retinal microvascular endothelial cells (hRMVECs) pretreated with genipin or transfected with UCP2siRNA, Glut1siRNA, or control siRNA when incubated with VEGF or PBS. RESULTS: At p14, OIR pups had increased AVA with decreased Glut1 and increased UCP2 in the retina compared to RA retinas. Intraperitoneal genipin increased retinal Glut1 and reduced AVA. Compared to control, treatment with genipin or knockdown of UCP2 significantly increased Glut1, glucose uptake, ATP production, VEGF-induced p-VEGFR2 and cell proliferation in hRMVECs. Knockdown of Glut1 inhibited VEGF-induced p-VEGFR2. Genipin-treated OIR pups with decreased AVA at p14 had reduced IVNV at p18 and increased amplitudes in a- and b-waves at p26. CONCLUSIONS: Extending PRVD by increasing retinal endothelial glucose uptake may represent a strategy to prevent severe retinopathy of prematurity and vision loss.
引用
- Han X, Kong J, Hartnett ME, et al. Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci. 2019. PMID: 30995317. doi:10.1167/iovs.19-26553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。